Opthea Limited Sponsored ADR (OPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

(NewsNation) — The number of drone sightings around the United States has dropped recently, but fewer people reporting seeing unidentified objects in the sky doesn’t mean there are more answers from ...

Rabat - Currently, on loan from West Ham, Nayef Aguerd is eager to make the most of his opportunity and help his team reach new heights. In an interview with Marca on December 21, Moroccan ...

Keppel FELS Limited (Keppel FELS), a wholly-owned subsidiary of Keppel Offshore & Marine (Keppel O&M) has secured a contract from TS Offshore Limited (TS Offshore), to construct an ultra-high ...

She is the founder and chief innovation officer of Opthea, a late-stage biopharmaceutical company developing a novel therapy to address the unmet need to treat retinal eye diseases. Dr Baldwin's ...

Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE ...

Opthea Limited, a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, announced that its CEO, Frederic Guerard, will present at the 43rd Annual J.P ...

MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage ...